An EU-funded project that aims to encourage the implementation of artificial intelligence-based personalised care for lung cancer patients – dubbed I3LUNG – has formally launched.<
Merck & Co has added another clinical-stage drug to its oncology pipeline via a licensing agreement with Finland's Orion for ODM-208, a prostate cancer candidate currently in phase 2 te
Roche's Genentech unit has gone all in on its collaboration with UK biotech Bicycle Therapeutics, taking up an option on a second additional target in the area of cancer immunotherapy.
Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics' lymphoma therapy Zynlonta – approved in the US last year – in Europe and other inte